GET DAILY SIGNALSAtara Biotherapeutics (ATRA): Can It Reach the $14 Analyst Target? (+69% Upside)
Key Takeaways
- The central target of $14 is the rounded arithmetic mean of three verified analyst price targets ($13.67), not a single firm's forecast.
- Atara Biotherapeutics, Inc. (ATRA) closed near $8.30, meaning the stock would need to rise roughly 69% to reach the target.
- The verified analyst range is wide, from $10 (Freedom Capital Markets) to $18 (Mizuho Securities), reflecting sharply divided views on FDA approval odds.
- The strongest support is the accepted resubmission of the tab-cel Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA).
- The biggest risks are a micro-cap balance sheet, very limited cash, and dependence on a single regulatory outcome.
- For more on this ticker, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- You can also track changing technical conditions using Trending AI Robots.
Analyst Price Targets and Consensus View
The central target of $14 is the arithmetic mean of three current, attributable analyst price targets: Canaccord Genuity (John Newman) at $13 with a Buy rating, reiterated in October 2026; Mizuho Securities (Salim Syed) at $18 with a Buy rating, maintained in August 2026; and Freedom Capital Markets at $10 with a Hold rating, set when the firm upgraded the stock from Sell in May 2026. Summed and divided by three, these produce a mean of $13.67, rounded to $14. The low-to-high range is $10 to $18, a wide spread that signals meaningful disagreement about the probability of U.S. approval for the company's lead therapy.
The bullish view hinges on tab-cel (tabelecleucel), an allogeneic T-cell immunotherapy for Epstein-Barr virus-associated post-transplant lymphoproliferative disease (PTLD). Canaccord's May upgrade from Hold to Buy, which raised its target from $6 to $13, cited a positive FDA Type A meeting and a potential approval pathway. Freedom Broker's upgrade from Sell to Hold, with a target raised from $4 to $10, reflected a similar shift, with the firm describing the probability of U.S. approval as "high" after an agreement on the design of a new filing. The cautious view, represented by the lower target, weighs the company's thin cash position and execution risk. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of late October 2026, ATRA traded near $8.30, with a 52-week range of roughly $3.92 to $19.15 and a market capitalization around $83 million. Reaching $14 from $8.30 implies an upside of approximately 69%, a very large move by any standard and one that would require a material re-rating of the shares.
The path toward that level runs almost entirely through a single binary event: FDA action on the resubmitted tab-cel BLA. Atara resubmitted the application in late September 2026, and the FDA accepted it for review in mid-October. Approval would unlock milestone and royalty payments from the company's European commercialization partner, Pierre Fabre, potentially transforming the company's financial profile. The alternative is a second Complete Response Letter, which would likely pressure the stock back toward its 52-week low.
What Could Support a Move Toward the Target
- FDA acceptance of the resubmitted BLA, a necessary step toward a U.S. approval decision on tab-cel.
- A partnership with Pierre Fabre that could deliver milestone and royalty payments without Atara bearing full commercialization costs.
- Positive momentum in analyst ratings, including the Canaccord and Freedom upgrades in 2026.
- A low share count and micro-cap valuation that can amplify upside on favorable news.
- Prior FDA agreement on the design of the new filing, which some analysts read as improving approval odds.
What Could Prevent the Target From Being Reached
- A second Complete Response Letter or other regulatory setback for tab-cel, the company's lead asset.
- A thin balance sheet: cash near $9.9 million as of the latest reported quarter, against an ongoing operating loss.
- Very limited trailing revenue of roughly $6.2 million, with minimal diversification across the pipeline after prior program suspensions.
- Dilution risk from a potential equity raise to fund operations through an approval decision.
- Wide analyst disagreement, with the lowest target at $10 sitting well below the $14 central figure.
Technical Levels and Market Structure
The shares have been consolidating below the 50-day simple moving average near $9.25 and the 200-day exponential moving average near $9.16, while holding above the 200-day simple moving average near $7.63. The $10 round-number level, which coincides with the lowest analyst target, marks an initial psychological hurdle, while the 52-week high near $19.15 sits above even the highest target. A durable support zone appears near $7.63, and a sustained move through the low-$9 range would be a necessary first step toward any re-rating toward the central target.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though each firm applies its own assumptions. For a story driven by a single regulatory decision, the effective catalyst timeline may be shorter. Investors should monitor the FDA review timeline and any communication from Atara or Pierre Fabre, the company's next earnings report, updates on cash runway and financing plans, and any revisions to analyst targets or ratings. Changes to the approval timeline, additional data requests from the FDA, or new financing announcements would be the most consequential developments. From what I see, tracking these elements closely helps clarify the setup.
Enhancing Research with AI Tools
In my own process, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor momentum shifts in event-driven names like this. The tool uses artificial intelligence to scan thousands of stocks and generate signals based on technical behavior and market conditions, which can complement manual review of regulatory timelines and financial metrics.
Final Assessment
Can Atara Biotherapeutics (ATRA) reach $14? The central target is the rounded mean ($13.67) of three analyst price targets spanning $10 to $18, and it implies a roughly 69% gain from the latest price near $8.30. The case for the move rests almost entirely on a successful FDA review of tab-cel, which would unlock milestone and royalty economics through Pierre Fabre. The case against it rests on a fragile cash position, minimal revenue, and the binary nature of the regulatory outcome. The wide analyst range underscores the uncertainty. Investors should focus on the FDA review timeline, cash runway, and any changes to analyst targets rather than treating the $14 figure as a forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ATRA in +2.95% Uptrend, advancing for three consecutive days on October 22, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ATRA advanced for three days, in 231 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
ATRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ATRA as a result. In 80 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ATRA turned negative on October 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 44 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
ATRA moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ATRA crossed bearishly below the 50-day moving average on October 26, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 62%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ATRA entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.266) is normal, around the industry mean (2.974). P/E Ratio (-5.458) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (22.883) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ATRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel therapeutics for serious unmet medical needs
Industry Biotechnology
Advertisement